Compare Manulife Financial Corporation (MFC) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Manulife Financial Corporation vs Novo Nordisk A/S — how do they compare? Manulife Financial Corporation trades at $43.99 (market cap $72.68B), while Novo Nordisk A/S trades at $46 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 2.9× Manulife Financial Corporation's market cap, and Novo Nordisk A/S pays the higher dividend (3.81%). Which is the better fit depends on your goals.
| MFC | NVO | |
|---|---|---|
Market Cap | $72.68B | $207.85B |
Sector | Financials | Health |
52-Week High | $44.77 | $63.98 |
52-Week Low | $30.06 | $35.29 |
Enterprise Value | $67.84B | $222.55B |
Dividend Yield | 3.1% | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Manulife Financial (MFC) trades at $44.15, down 0.38% on the day, with a bullish technical signal from moving averages and neutral oscillators. Revenue grew to $53.01B in 2025, with net income of $5.78B, and the company has a strong analyst consensus of 57% buy ratings. Recent Q2 2026 earnings beat expectations, driven by Asia growth and insurance sales, while dividends of $0.49 per share were declared for H1 and H2 2026.
MFC's outlook is positive due to earnings momentum and strategic AI partnerships, but risks include premium valuation and segment volatility. The stock offers steady dividends and growth potential, though investors should monitor execution in wealth management and macroeconomic impacts on insurance demand.
NVO trades at $47.73, up 0.99% today, with a neutral technical signal and strong fundamentals, including a P/E of 11.62 and net income margin of 35.35%. Recent Q2 2026 earnings beat expectations, but the stock faces mixed sentiment due to competitive pressures and pricing headwinds in its GLP-1 portfolio.
The outlook is cautiously optimistic, supported by robust profitability and analyst buy ratings (57.9%), but risks include intense competition from Eli Lilly and margin compression. Upside potential hinges on execution against guidance, while downside risks stem from market share erosion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Manulife Financial Corporation
Manulife provides life insurance and wealth management products and services to individuals and group customers in Canada, the United States, and Asia. Manulife is one of Canada's Big Three Life Insurance companies (the other two are Sun Life and Great West Life). As of Dec. 31, 2021, Manulife reported assets under management or administration of about CAD $1.4 trillion.
Read more on MFC →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
